Lexicon Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LXRX research report →
Range $6 – $6
Price Chart
About the company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain.
- CEO
- Michael S. Exton
- IPO
- 2000
- Employees
- 81
- HQ
- The Woodlands, TX, US
Get TickerSpark's AI analysis on LXRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $681.21M
- P/E
- -11.49
- Fwd P/E
- 42.50
- PEG
- 0.10
- P/S
- 19.29
- P/B
- 4.54
- EV/EBITDA
- -13.51
- Div Yield
- 0.00%
- Gross Margin
- 98.59%
- Op Margin
- -147.42%
- Net Margin
- -161.80%
- ROE
- -38.44%
- ROIC
- -25.15%
Latest fiscal year · YoY change
- Revenue
- $49.80M+60.2%
- Gross Profit
- $49.53M+62.6%
- Op Income
- $-48,911,000
- Net Income
- $-50,341,000+74.9%
- EPS
- $-0.14+77.8%
- OCF Growth
- +62.0%
- FCF Growth
- +62.3%
- 52W High
- $2.68
- 52W Low
- $1.10
- 50D MA
- $1.74
- 200D MA
- $1.90
- Beta
- 1.08
- RSI (14)
- 44
- Avg Volume
- 2.54M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Lexicon said it is entering a potentially transformational 12 months, with SONATA-HCM enrollment complete, a ZYNQUISTA NDA resubmission targeted for Q1 2027, and preclinical pilavapadin obesity data adding a new angle to the pipeline.· November 5, 2026
- SONATA-HCM completed enrollment with 542 patients and top-line results expected in Q1 2027.
- ZYNQUISTA NDA resubmission is now expected in Q1 2027, supported by STENO1 safety data showing DKA around one event per 100 patient-years.
- Q3 revenue was $11.3 million versus $14.2 million a year ago; the quarter included $10 million of Novo Nordisk milestone revenue and $1.2 million of INPEFA sales.
- Pilavapadin showed early preclinical weight-loss activity, including 14% body-weight reduction alone and 31% with semaglutide in mice.
- Lexicon kept 2026 operating expense guidance unchanged at $100 million to $110 million, with cash and short-term investments at $183.2 million at quarter-end.
Lexicon reported third-quarter 2026 revenue of $11.3 million, down from $14.2 million in the prior-year quarter. Revenue included $10 million of milestone revenue from Novo Nordisk and $1.2 million of INPEFA net sales, versus $13.2 million of Novo licensing revenue and $1.0 million of INPEFA sales a year ago. R&D expense was $16.2 million, compared with $18.8 million last year; SG&A was $9.5 million, compared with $7.6 million; and net loss was $14.0 million, or $0.03 per share, versus a net loss of $12.8 million, or $0.04 per share. Cash, cash equivalents, and short-term investments were $183.2 million as of September 30, 2026, versus $125.2 million at December 31, 2025. Management maintained 2026 operating expense guidance of $100 million to $110 million, with R&D expected at $63 million to $68 million and SG&A at $37 million to $42 million. Next major catalysts are SONATA-HCM top-line data in Q1 2027 and ZYNQUISTA NDA resubmission in Q1 2027.
Mike Exton framed the quarter as part of a “potentially transformational” period for Lexicon, pointing to multiple near-term catalysts across HCM, type 1 diabetes, LX9851, and pilavapadin. He emphasized that SONATA-HCM was designed to reflect real-world HCM practice across both obstructive and non-obstructive patients, and he repeatedly highlighted sotagliflozin’s once-daily oral profile and differentiated mechanism. On ZYNQUISTA, he stressed the company’s commitment to resubmission despite delays, and on pilavapadin he signaled a possible expansion into obesity/weight management if the early data continue to look encouraging.
Scott Coiante walked through a quarter with modest revenue and earnings pressure but solid balance-sheet support. He cited $11.3 million of revenue, $16.2 million of R&D expense, $9.5 million of SG&A, and a $14.0 million net loss, while noting that stock-based compensation was $3.4 million in both the current and prior-year quarters. He said Lexicon ended the quarter with $183.2 million in cash equivalents and short-term investments and reiterated full-year 2026 operating expense guidance of $100 million to $110 million, including targeted pre-commercial spending.
Analysts focused heavily on SONATA-HCM design and readout questions, especially the large non-obstructive population, the lower baseline KCCQ in the obstructive cohort, and whether the trial could support a broad HCM label if subgroup results differ. Management said the mix was not surprising given real-world referral patterns and the use of academic centers, and said the key label question would likely come down to directionality and interaction testing rather than perfect subgroup symmetry. On T1D, management explained that the delay in NDA resubmission is largely administrative and data-preparation related because STENO1 was investigator-initiated and not built like a regulatory study; they said the FDA-required patient exposure threshold has now been met and the package is being prepared for Q1 2027 submission. Analysts also pressed on pilavapadin’s weight-loss mechanism and human tolerability, and management said early human weight loss was seen in PROGRESS, while the new obesity work is still preclinical and could support a future proof-of-concept study.
The bullish view from the call is that Lexicon has multiple identifiable catalysts in the next six to 12 months, with both SONATA-HCM and the ZYNQUISTA resubmission targeted for Q1 2027. Management sounded confident in the STENO1 DKA data, the breadth of the SONATA population, and the potential for pilavapadin to open an additional obesity/weight-management opportunity.
The main risks discussed were timing and execution: the ZYNQUISTA resubmission is later than originally expected because the STENO1 dataset required substantial cleanup and regulatory formatting, and SONATA-HCM still has an unblinded outcome ahead with no guarantee of success. Investors also heard that pilavapadin’s obesity angle is still early and preclinical, and that the HCM market will be competitive with multiple mechanisms and potential label and hierarchy questions still unresolved.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 49.2%
- Shares Outstanding
- 445.23M
- Float Shares
- 219.12M
of shares held by institutions
157 13F filers
Buy/sell ratio 2.88. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Artal Group S.A. | 175.16M | 0 |
| Fmr LLC | 66.74M | ▲ 14.96M |
| Siren, L.L.C. | 44.30M | 0 |
| Sessa Capital Im, L.P. | 18.96M | ▲ 1.05M |
| Blackrock, Inc. | 16.80M | ▼ 549.21K |
| Vanguard Capital Management LLC | 9.73M | ▼ 167.65K |
| Vanguard Group Inc | 9.61M | ▲ 84.67K |
| Point72 Asset Management, L.P. | 8.25M | ▲ 436.72K |
| State Street Corp | 7.47M | ▲ 2.55M |
| Geode Capital Management, LLC | 5.89M | ▼ 352.40K |
| Vanguard Portfolio Management LLC | 2.89M | ▲ 532.97K |
| Northern Trust Corp | 1.97M | ▲ 1.47M |
Held by 146 ETFs
Biggest fund positions in LXRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Exton Michael | buy | 30,064 |
| Jun 3, 26 | Swain Judith L | other | 89,312 |
| Jun 3, 26 | Swain Judith L | other | 89,312 |
| Jun 3, 26 | Sullivan Diane E. | other | 89,312 |
| Jun 3, 26 | Sullivan Diane E. | other | 89,312 |
| Jun 3, 26 | SOBECKI CHRISTOPHER J | other | 89,312 |
| Jun 3, 26 | SOBECKI CHRISTOPHER J | other | 89,312 |
| Jun 3, 26 | Cheung Ivan | other | 89,312 |
| Jun 3, 26 | Cheung Ivan | other | 89,312 |
| Jun 3, 26 | BARKER SAM L | other | 89,312 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LXRX coverage
Recent articles, reports, and earnings notes.
No research on LXRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LXRX report →Lexicon Pharmaceuticals Sets Sights on Heart Trial Results, Diabetes Drug Resubmission in 2027
marketbeat.com · Nov 20
Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 11
New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
globenewswire.com · Nov 9
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 5
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
globenewswire.com · Nov 5
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
globenewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.